EC Approves Sanofi and Regeneron’s Dupixent® for Eosinophilic Esophagitis
The European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreThe U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use
Read moreQIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, announced on Monday the launch of their enhanced QIAGEN CLC Genomics
Read morePharma giant Pfizer Inc. and the Global Partner Research Organization (PRO) for integrated bench-to-market solutions for biologics and bioconjugates, Abzena, announced
Read moreKinaxis® Inc., the leading authority in driving agility for fast, confident decision-making in an unpredictable world, announced last month that
Read moreLonza and Context Therapeutics, a US-based clinical-stage biopharmaceutical company advancing therapeutics for solid tumors, announced that they have reached a
Read moreFrench clinical-stage biotech company Sensorion, which focuses on the creation of cutting-edge treatments to manage, prevent, and reverse hearing loss
Read moreBoehringer Ingelheim and Click Therapeutics announced on December 19, that they will expand their existing collaboration to develop and commercialize
Read morePfizer Inc. (NYSE: PFE) announced in late December, positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read more